Multidisciplinary Cancer Investigation
Tue, Oct 8, 2024
[Archive]
Volume 8, Issue 1 (Multidisciplinary Cancer Investigation 2024)
Multidiscip Cancer Investig 2024, 8(1): 0-0 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mermit Erçek B, Mermit B, Karaman E. Venous Thromboembolism Prophylaxis in Gynecological Oncology: The review of guidelines. Multidiscip Cancer Investig 2024; 8 (1)
URL: http://mcijournal.com/article-1-374-en.html
URL: http://mcijournal.com/article-1-374-en.html
1- Department of Medical Oncology, Faculty of Medicine, Van Yuzuncu Yıl University, Van, Turkey
2- Department of Pulmunology, Faculty of Medicine, Van Yuzuncu Yıl University, Van, Turkey ,buketmermitcilingir@gmail.com
3- Department of Gynecological Oncology, Faculty of Medicine, Van Yuzuncu Yıl University, Van, Turkey
2- Department of Pulmunology, Faculty of Medicine, Van Yuzuncu Yıl University, Van, Turkey ,
3- Department of Gynecological Oncology, Faculty of Medicine, Van Yuzuncu Yıl University, Van, Turkey
Abstract: (642 Views)
Venous thromboembolism (VTE) is one of the leading causes of death in cancer patients. VTE prophylaxis and/or treatment in the treatment and follow-up of cancer patients will reduce mortality and morbidity rates. Although the incidence of VTE in cancer patients is high, there is not yet a standardized protocol for the prevention of VTE in the subgroup of gynecological cancer patients. VTE prophylaxis and treatment vary according to the cancer type of the patients and the treatment approaches to be applied. In this review, it is aimed to explain the pathogenesis, risk factors and treatment approaches in VTE prophylaxis in gynecological oncology patients, taking into account international consensus reports. All reviewed guidelines recommended VTE prophylaxis for all hospitalized patients with active cancer. All guidelines agree that low molecular weight heparin (LMWH) gives good results in VTE prophylaxis in patients diagnosed with gynecological cancer. Risk scoring has been recommended for outpatients after discharge, and current guidelines recommend direct oral anticoagulants (DOAC) for the prevention of VTE in high-risk patients. Due to the high risk of bleeding in the gynecological cancer patient population, the side effects of pharmacological agents should be well considered and more attention should be paid to mechanical prophylactic methods.
Select article type: Review Article |
Subject:
Prevention, Early Detection and Screening
Received: 2023/01/13 | Accepted: 2023/07/25 | ePublished: 2024/01/8
Received: 2023/01/13 | Accepted: 2023/07/25 | ePublished: 2024/01/8
References
1. Chung I, Lip GY. Virchow's triad revisited: blood constit¬uents. Pathophysiol Haemost Thromb. 2003;33(5-6):449- 54. DOI: 10.1159/000083844 PMID: 15692259. [DOI:10.1159/000083844] [PMID]
2. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombo¬sis. Arterioscler Thromb Vasc Biol. 2007;27(8):1687-93. DOI: 10.1161/ATVBAHA.107.141911 PMID: 17556654. [DOI:10.1161/ATVBAHA.107.141911] [PMID]
3. Sack GH, Jr., Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore). 1977;56(1):1- 37. PMID: 834136. [DOI:10.1097/00005792-197701000-00001] [PMID]
4. Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, et al. Rates of initial and recurrent throm¬boembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78(5):285-91. DOI: 10.1097/00005792-199909000-00001 PMID: 10499070. [DOI:10.1097/00005792-199909000-00001] [PMID]
5. Falanga A, Donati MB. Pathogenesis of thrombosis in pa¬tients with malignancy. Int J Hematol. 2001;73(2):137-44. DOI: 10.1007/BF02981929 PMID: 11372723. [DOI:10.1007/BF02981929] [PMID]
6. Rickles FR, Falanga A. Molecular basis for the re¬lationship between thrombosis and cancer. Thromb Res. 2001;102(6):V215-24. DOI: 10.1016/s0049- 3848(01)00285-7 PMID: 11516455. [DOI:10.1016/S0049-3848(01)00285-7] [PMID]
7. Khorana AA, Francis CW, Culakova E, Kuderer NM, Ly¬man GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632-4. DOI: 10.1111/j.1538- 7836.2007.02374.x PMID: 17319909. [DOI:10.1111/j.1538-7836.2007.02374.x] [PMID]
8. Piccioli A, Prandoni P, Ewenstein BM, Goldhaber SZ. Cancer and venous thromboembolism. Am Heart J. 1996;132(4):850-5. DOI: 10.1016/s0002-8703(96)90321-x PMID: 8831376. [DOI:10.1016/S0002-8703(96)90321-X] [PMID]
9. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malig¬nancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715-22. DOI: 10.1001/ jama.293.6.715 PMID: 15701913. [DOI:10.1001/jama.293.6.715] [PMID]
10. Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among am¬bulatory high-risk cancer patients undergoing chemothera¬py in the United States. Cancer. 2013;119(3):648-55. DOI: 10.1002/cncr.27772 PMID: 22893596. [DOI:10.1002/cncr.27772] [PMID]
11. Satoh T, Matsumoto K, Tanaka YO, Akiyama A, Nakao S, Sakurai M, et al. Incidence of venous thromboembolism before treatment in cervical cancer and the impact of man¬agement on venous thromboembolism after commence¬ment of treatment. Thromb Res. 2013;131(4):e127-32. DOI: 10.1016/j.thromres.2013.01.027 PMID: 23433998. [DOI:10.1016/j.thromres.2013.01.027] [PMID]
12. Tasaka N, Minaguchi T, Hosokawa Y, Takao W, Itagaki H, Nishida K, et al. Prevalence of venous thromboembolism at pretreatment screening and associated risk factors in 2086 patients with gynecological cancer. J Obstet Gynaecol Res. 2020;46(5):765-73. DOI: 10.1111/jog.14233 PMID: 32147891. [DOI:10.1111/jog.14233] [PMID]
13. Maxwell GL, Myers ER, Clarke-Pearson DL. Cost-effec¬tiveness of deep venous thrombosis prophylaxis in gyneco¬logic oncology surgery. Obstet Gynecol. 2000;95(2):206- 14. DOI: 10.1016/s0029-7844(99)00563-3 PMID: 10674581. [DOI:10.1016/S0029-7844(99)00563-3] [PMID]
14. Karaman E, Aydiner B, Çilingir BM, Hacioglu L. Clinical evaluation of pulmonary thromboembolism in gynecologic oncology operations: Analysis of nine patients in a univer¬sity hospital. Eastern J Med. 2022;27(4):596-600. [DOI:10.5505/ejm.2022.03780]
15. Rauh-Hain JA, Hariton E, Clemmer J, Clark RM, Hall T, Boruta DM, et al. Incidence and effects on mortality of venous thromboembolism in elderly women with endome¬trial cancer. Obstet Gynecol. 2015;125(6):1362-70. DOI: 10.1097/AOG.0000000000000866 PMID: 26000507. [DOI:10.1097/AOG.0000000000000866] [PMID]
16. Glickman A, Brennecke A, Tayebnejad A, Matsuo K, Guntupalli SR, Sheeder J. Cost-effectiveness of apixaban for prevention of venous thromboembolic events in pa¬tients after gynecologic cancer surgery. Gynecol Oncol. 2020;159(2):476-82. DOI: 10.1016/j.ygyno.2020.07.096 PMID: 32854972. [DOI:10.1016/j.ygyno.2020.07.096] [PMID]
17. Barber EL, Clarke-Pearson DL. The limited utility of currently available venous thromboembolism risk as¬sessment tools in gynecological oncology patients. Am J Obstet Gynecol. 2016;215(4):445 e1-9. DOI: 10.1016/j. ajog.2016.04.034 PMID: 27131583. [DOI:10.1016/j.ajog.2016.04.034] [PMID] []
18. Lavikainen LI, Guyatt GH, Lee Y, Couban RJ, Luomaranta AL, Sallinen VJ, et al. Systematic reviews of observation¬al studies of Risk of Thrombosis and Bleeding in General and Gynecologic Surgery (ROTBIGGS): introduction and methodology. Syst Rev. 2021;10(1):264. DOI: 10.1186/ s13643-021-01814-2 PMID: 34625092. [DOI:10.1186/s13643-021-01814-2] [PMID] []
19. Streiff MB, Abutalib SA, Farge D, Murphy M, Con¬nors JM, Piazza G. Update on Guidelines for the Man¬agement of Cancer-Associated Thrombosis. Oncologist. 2021;26(1):e24-e40. DOI: 10.1002/onco.13596 PMID: 33275332. [DOI:10.1002/onco.13596] [PMID] []
20. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous Thromboembolism Prophylax¬is and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2020;38(5):496- 520. DOI: 10.1200/JCO.19.01461 PMID: 31381464. [DOI:10.1200/JCO.19.01461] [PMID]
21. Italian Association of Medical Oncology. AIOM Guide¬lines for Venous Thromboembolism in Patients With Solid Tumors. Italy: IOM, 2018.
22. Munoz Martin AJ, Gallardo Diaz E, Garcia Escobar I, Macias Montero R, Martinez-Marin V, Pachon Olmos V, et al. SEOM clinical guideline of venous thrombo¬embolism (VTE) and cancer (2019). Clin Transl Oncol. 2020;22(2):171-86. DOI: 10.1007/s12094-019-02263-z PMID: 31981080. [DOI:10.1007/s12094-019-02263-z] [PMID]
23. Watson HG, Keeling DM, Laffan M, Tait RC, Makris M, British Committee for Standards in H. Guideline on as¬pects of cancer-related venous thrombosis. Br J Haema¬tol. 2015;170(5):640-8. DOI: 10.1111/bjh.13556 PMID: 26114207. [DOI:10.1111/bjh.13556] [PMID]
24. Siragusa S, Armani U, Carpenedo M, Falanga A, Fulfaro F, Imberti D, et al. Prevention of venous thromboembolism in patients with cancer: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)(1). Thromb Res. 2012;129(5):e171-6. DOI: 10.1016/j.thromres.2011.09.002 PMID: 21962722. [DOI:10.1016/j.thromres.2011.09.002] [PMID]
25. Easaw JC, Shea-Budgell MA, Wu CM, Czaykowski PM, Kassis J, Kuehl B, et al. Canadian consensus recommen¬dations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis. Curr Oncol. 2015;22(2):133-43. DOI: 10.3747/co.22.2586 PMID: 25908912. [DOI:10.3747/co.22.2586] [PMID] []
26. Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, et al. American Society of Hematology 2021 guidelines for management of venous thromboem¬bolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927-74. DOI: 10.1182/bloodadvanc¬es.2020003442 PMID: 33570602. [DOI:10.1182/bloodadvances.2021004734] [PMID] []
27. Falanga A, Ay C, Di Nisio M, Gerotziafas G, Jara-Palo¬mares L, Langer F, et al. Venous thromboembolism in can¬cer patients: ESMO Clinical Practice Guideline. Ann Oncol. 2023;34(5):452-67. DOI: 10.1016/j.annonc.2022.12.014 PMID: 36638869. [DOI:10.1016/j.annonc.2022.12.014] [PMID]
28. Douketis JD, Frere C, Farge D. International Thrombosis and Cancer Initiative members. 2019 international clinical practice guidelines for the treatment of venous thromboem¬bolism - Authors' reply. Lancet Oncol. 2019;20(12):e656. DOI: 10.1016/S1470-2045(19)30750-8 PMID: 31797782. [DOI:10.1016/S1470-2045(19)30750-8] [PMID]
29. Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thromb Haemost. 2017;117(2):219-30. DOI: 10.1160/ TH16-08-0615 PMID: 27882374. [DOI:10.1160/TH16-08-0615] [PMID]
30. Hull RD, Pineo GF, Stein PD, Mah AF, MacIsaac SM, Dahl OE, et al. Timing of initial administration of low-molecu¬lar-weight heparin prophylaxis against deep vein thrombo¬sis in patients following elective hip arthroplasty: a system¬atic review. Arch Intern Med. 2001;161(16):1952-60. DOI: 10.1001/archinte.161.16.1952 PMID: 11525697. [DOI:10.1001/archinte.161.16.1952] [PMID]
31. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thrombo¬embolism: American College of Chest Physicians Evi¬dence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):381S-453S. DOI: 10.1378/ chest.08-0656 PMID: 18574271. [DOI:10.1378/chest.08-0656] [PMID]
32. Turner GM, Cole SE, Brooks JH. The efficacy of gradu¬ated compression stockings in the prevention of deep vein thrombosis after major gynaecological surgery. Br J Ob¬stet Gynaecol. 1984;91(6):588-91. DOI: 10.1111/j.1471- 0528.1984.tb04808.x PMID: 6733063. [DOI:10.1111/j.1471-0528.1984.tb04808.x] [PMID]
33. Clarke-Pearson DL, Synan IS, Hinshaw WM, Coleman RE, Creasman WT. Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynecologic malignancy. Obstet Gynecol. 1984;63(1):92-8. PMID: 6691021.
34. Clarke-Pearson DL, Creasman WT, Coleman RE, Synan IS, Hinshaw WM. Perioperative external pneumatic calf compression as thromboembolism prophylaxis in gyne¬cologic oncology: report of a randomized controlled trial. Gynecol Oncol. 1984;18(2):226-32. DOI: 10.1016/0090- 8258(84)90030-1 PMID: 6376294. [DOI:10.1016/0090-8258(84)90030-1] [PMID]
35. Feng JP, Xiong YT, Fan ZQ, Yan LJ, Wang JY, Gu ZJ. Ef¬ficacy of intermittent pneumatic compression for venous thromboembolism prophylaxis in patients undergoing gy¬necologic surgery: A systematic review and meta-analysis. Oncotarget. 2017;8(12):20371-9. DOI: 10.18632/oncotar¬get.13620 PMID: 27901494. [DOI:10.18632/oncotarget.13620] [PMID] []
36. Turpie AG. Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MED¬ical patients with ENOXaparin (MEDENOX) trial. Am J Cardiol. 2000;86(12B):48M-52M. DOI: 10.1016/s0002- 9149(00)01481-8 PMID: 11206019. [DOI:10.1016/S0002-9149(00)01481-8] [PMID]
37. Carrier M, Khorana AA, Moretto P, Le Gal G, Karp R, Zwicker JI. Lack of evidence to support thromboprophylax¬is in hospitalized medical patients with cancer. Am J Med. 2014;127(1):82-6 e1. DOI: 10.1016/j.amjmed.2013.09.015 PMID: 24384102. [DOI:10.1016/j.amjmed.2013.09.015] [PMID]
38. Bergqvist D, Agnelli G, Cohen AT, Nilsson PE, Moi¬gne-Amrani AL, Dietrich-Neto F. Prolonged prophy¬laxis against venous thromboembolism with enoxapa¬rin in patients undergoing cancer surgery: long-term survival analysis. Phlebology. 2006;21(4):195-8. DOI: 10.1258/026835506779115753. [DOI:10.1258/026835506779115753]
39. Martino MA, George JG, Chen CC, Galic V, Kapoor R, Murray KC, et al. Preoperative enoxaparin is safe to use in major gynecologic surgery for prophylaxis of ve¬nous thromboembolism: a retrospective cohort study. Int J Gynecol Cancer. 2012;22(4):681-5. DOI: 10.1097/ IGC.0b013e3182454499 PMID: 22343972. [DOI:10.1097/IGC.0b013e3182454499] [PMID]
40. Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg. 2006;243(1):89-95. DOI: 10.1097/01.sla.0000193959.44677.48 PMID: 16371741. [DOI:10.1097/01.sla.0000193959.44677.48] [PMID] []
41. Peedicayil A, Weaver A, Li X, Carey E, Cliby W, Mari¬ani A. Incidence and timing of venous thromboembolism after surgery for gynecological cancer. Gynecol Oncol. 2011;121(1):64-9. DOI: 10.1016/j.ygyno.2010.11.038 PMID: 21183211. [DOI:10.1016/j.ygyno.2010.11.038] [PMID]
42. Committee on Practice Bulletins--Gynecology ACoO, Gy¬necologists. ACOG Practice Bulletin No. 84: Prevention of deep vein thrombosis and pulmonary embolism. Ob¬stet Gynecol. 2007;110(2 Pt 1):429-40. DOI: 10.1097/01. AOG.0000263919.23437.15 PMID: 17666620. [DOI:10.1097/01]
43. Amaragiri SV, Lees TA. Elastic compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev. 2000(3):CD001484. DOI: 10.1002/14651858. CD001484 PMID: 10908501. [DOI:10.1002/14651858] [PMID] []
44. Guntupalli SR, Brennecke A, Behbakht K, Tayebnejad A, Breed CA, Babayan LM, et al. Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Ve¬nous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial. JAMA Netw Open. 2020;3(6):e207410. DOI: 10.1001/jamanetworkopen.2020.7410 PMID: 32589230. [DOI:10.1001/jamanetworkopen.2020.7410] [PMID] []
45. Douros A, Filliter C, Azoulay L, Tagalakis V. Effectiveness and safety of direct oral anticoagulants in patients with cancer associated venous thromboembolism. Thromb Res. 2021;202:128-33. DOI: 10.1016/j.thromres.2021.03.026 PMID: 33836492. [DOI:10.1016/j.thromres.2021.03.026] [PMID]
46. Togna GI, Togna AR, Franconi M, Caprino L. Cisplatin triggers platelet activation. Thromb Res. 2000;99(5):503-9. DOI: 10.1016/s0049-3848(00)00294-2 PMID: 10973681. [DOI:10.1016/S0049-3848(00)00294-2] [PMID]
47. Bamias A, Tzannis K, Zakopoulou R, Sakellakis M, Dimi¬triadis J, Papatheodoridi A, et al. Risk for Arterial Thrombo¬embolic Events (ATEs) in Patients with Advanced Urinary Tract Cancer (aUTC) Treated with First-Line Chemo¬therapy: Single-Center, Observational Study. Curr Oncol. 2022;29(9):6077-90. DOI: 10.3390/curroncol29090478 PMID: 36135047. [DOI:10.3390/curroncol29090478] [PMID] []
48. Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tab¬bara NE, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011;29(25):3466-73. DOI: 10.1200/JCO.2011.35.5669 PMID: 21810688. [DOI:10.1200/JCO.2011.35.5669] [PMID] []
49. Yu M, Han J, Cui P, Dai M, Li H, Zhang J, et al. Cis¬platin up-regulates ICAM-1 expression in endothelial cell via a NF-kappaB dependent pathway. Cancer Sci. 2008;99(2):391-7. DOI: 10.1111/j.1349-7006.2008.00696.x PMID: 18271937. [DOI:10.1111/j.1349-7006.2008.00696.x] [PMID] []
50. Shi Y, Inoue S, Shinozaki R, Fukue K, Kougo T. Release of cytokines from human umbilical vein endothelial cells treated with platinum compounds in vitro. Jpn J Cancer Res. 1998;89(7):757-67. DOI: 10.1111/j.1349-7006.1998. tb03281.x PMID: 9738983. [DOI:10.1111/j.1349-7006.1998.tb03281.x] [PMID] []
51. Mikula-Pietrasik J, Witucka A, Pakula M, Uruski P, Begi¬er-Krasinska B, Niklas A, et al. Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells. Cell Mol Life Sci. 2019;76(4):681-97. DOI: 10.1007/s00018-018-2954-1 PMID: 30382284. [DOI:10.1007/s00018-018-2954-1] [PMID] []
52. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandala M, Cavanna L, et al. Nadroparin for the prevention of throm¬boembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemothera¬py: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10(10):943-9. DOI: 10.1016/S1470- 2045(09)70232-3 PMID: 19726226. [DOI:10.1016/S1470-2045(09)70232-3] [PMID]
53. Liakishev AA. [Dabigatran versus warfarin in the treat¬ment of acute venous thromboembolism. Results of the RE-COVER study]. Kardiologiia. 2010;50(3):80-1. PMID: 20459411.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
